News

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Search form

Media Contact

Stephen Schultz
VP Investor Relations (U.S.)
T: 917-280-2424 / 401 500 6570
sschultz@gwpharm.com
 

Recent Press Releases

Aug 28, 2014
GW Pharmaceuticals to Present at Upcoming Investor Conferences
London, UK, 28 August 2014: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics
Read more...
Aug 06, 2014
GW Pharmaceuticals plc Reports 2014 Third Quarter Financial Results
-Conference Call Today at 8:00 a.m. ET, 1:00 p.m. BST-
Read more...
Jul 30, 2014
GW Pharmaceuticals to Report Q3 2014 Financial Results and Host Conference Call on 6 August, 2014
London, UK, 30 July 2014: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its propri
Read more...
Jun 25, 2014
GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Totaling Approximately $169.8 Million on the NASDAQ Global Market
LONDON, UK, 25 June, 2014 -- GW Pharmaceuticals plc (Nasdaq: GWPH) (AIM: GWP) ("GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its p
Read more...
Jun 18, 2014
GW Pharmaceuticals plc Announces Pricing of U.S. Public Offering of ADSs Totaling Approximately $148 Million on NASDAQ Global Market
London, UK, 18 June 2014: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its propri
Read more...
Jun 17, 2014
GW Pharmaceuticals Announces Physician Reports of Epidiolex® Treatment Effect in Children and Young Adults with Treatment-Resistant Epilepsy from Physician-Led Expanded Access Treatment Program
- Data show promising signals of efficacy and safety -  
Read more...
Jun 17, 2014
GW Pharmaceuticals Announces Proposed Public Offering of ADSs
London, UK, 17 June 2014: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its propri
Read more...
Jun 06, 2014
GW Pharmaceuticals Announces Epidiolex® Receives Fast Track Designation from FDA for the Treatment of Dravet Syndrome
London, UK; 6 June 2014: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics fro
Read more...
Jun 03, 2014
GW announces agreement with New York State to investigate use of CBD to treat medication-resistant epilepsies in children
London, UK, 3 June 2014: GW Pharmaceuticals plc (NASDAQ: GWPH, AIM: GWP, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics fro
Read more...
May 27, 2014
A State of Georgia initiative making it possible to treat children with epilepsy with cannabidiol is moving forward
Atlanta, Georgia, and London, UK 27 May 2014: A State of Georgia initiative making it possible to treat children with epilepsy with cannabidiol is moving forward.
Read more...

Pages